Effects of Low-Load Blood Flow Restriction Resistance Training With and Without Hip Abductor Strengthening in Patients With Knee Osteoarthritis (BFR) (yes)

November 13, 2026 updated by: Salman Bashir, University of Management and Technology Lahore

Effects of Low-Load Blood Flow Restriction Resistance With and Without Hip Abductor Strength Training on Pain, Range of Motion, Strength and Function in Patients With Knee Osteoarthritis

This study aims to compare the effects of low-load Blood Flow Restriction (BFR) resistance training with and without hip abductor strengthening in patients with knee osteoarthritis. It will evaluate the effectiveness of both treatment approaches in reducing knee pain, improving range of motion, increasing muscle strength, and enhancing functional ability. The study will determine which intervention provides better clinical outcomes in patients with knee osteoarthritis.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 54000
        • University of Management & Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Both genders.
  • Age 40-60 years.
  • BMI (kg/m 2 ) < 30
  • Have unilateral or bilateral knee OA.
  • Have radiographic OA severity of Kellgren-Lawrence Grade I-II.
  • Knee pain ≥3 months.
  • Report pain intensity of ≥4-6/1 0 on NPRS
  • Be able to walk independently without assistive devices

Exclusion Criteria:

  • Total Knee replacement
  • Deep venous thrombosis.
  • Severe Cardiovascular disorders.(such as Acute myocardial
  • infarction, peripheral arterial disease)
  • Uncontrolled hypertension and diabetes.
  • Acute knee injury within the last 6 months.
  • Significant ligament tears (ACL, PCL, MCL, LCL).
  • Knee surgery within the last 6-1 2 months.
  • Lower limb Fractures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Low-Load Blood Flow Restriction Resistance Training

Participants will receive supervised low-load BFR training targeting quadriceps and hamstrings through seated knee extensions, leg presses (bilateral/unilateral), and progressive mini squats at 20-30% of 1RM.Each exercise includes 4 sets (30-15-15-15 repetitions), with 30-60 seconds of rest between sets while the cuff remains inflated, followed by immediate deflation after the final set.

Experimental: Hip abductor strength training followed by low-load BFR resistance training

Participants will receive hip abductor strengthening for Weeks 2-4, followed by BFR resistance training during Weeks 5-6, under physiotherapist supervision.

Exercises include side-lying hip abduction, clamshells, standing resisted hip abduction, and lateral band walks (3 sets of 10-15 repetitions or 10 lateral steps per direction), with 60-second rest intervals.

Training will begin with bodyweight exercises, progressing to TheraBand resistance from Week 2, without BFR cuff application during hip exercises.

Weeks 5-6: Participants will receive BFR training (knee extensions and leg presses) at 20-30% of 1RM, 70% arterial occlusion pressure (AOP), and 4 sets of 30-15-15-15 repetitions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numeric Pain Rating Scale
Time Frame: Baseline and 6 weeks post treatment

11-point numeric with 0 representing No pain, 1-3 representing Mild Pain (nagging, annoying, interfering little with ADLs), 4-6 representing Moderate Pains (interferes significantly with ADLs), 7-10 representing Sever Pain

Baseline and 6 weeks post treatment
Western Ontario And McMasters Universities Osteoarthritis Index
Time Frame: Baseline and 6 weeks post treatment

The WOMAC is a disease-specific questionnaire designed to assess symptoms and functional limitations in individuals with knee and hip osteoarthritis. It consists of 24 items divided into three domains: Pain (5 items), Stiffness (2 items), and Physical.Function (1 7 items). The WOMAC is widely used to evaluate the impact of osteoarthritis on daily activities and quality of life.Higher WOMAC scores indicate greater pain, stiffness, and functional disability, whereas lower scores represent betterfunctional status and symptom improvement.

Baseline and 6 weeks post treatment
Goniometer
Time Frame: Baseline and 6 weeks post treatment

A goniometer is a reliable clinical tool used to measure knee flexion and extension ROM in patients with knee osteoarthritis, assess joint mobility, monitor disease progression, and evaluate rehabilitation outcomes. Normal knee flexion is approximately 135°-140° and extension is 0°. Reduced ROM indicates stiffness, pain, or functional limitations.

Baseline and 6 weeks post treatment
Handheld Dynamometer
Time Frame: Baseline and 6 weeks post treatment

A handheld dynamometer (HHD) is a portable, objective tool used to measure isometric muscle strength at a fixed joint position. It records maximum muscle force in Newtons (N) or kilograms-force (kgf), with higher values indicating greater muscle strength.

Baseline and 6 weeks post treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Short form 1 2 Health Survey
Time Frame: Baseline and 6 weeks post treatment

The SF-12 is a validated, reliable, and shorter version of the SF-36 that assesses physical (PCS) and mental (MCS) components of quality of life in knee osteoarthritis patients. Lower baseline scores indicate physical impairment or emotional burden, while increased post-intervention scores reflect improved physical and mental health. A change of approximately 3-5 points may be considered clinically meaningful, depending on the population and scoring method.

Baseline and 6 weeks post treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 20, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

October 17, 2026

First Submitted That Met QC Criteria

October 17, 2026

First Posted (Actual)

October 23, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Time Frame

6 months after the publication of the manuscript

IPD Sharing Access Criteria

The data can be requested from the corresponding author.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe